Hope for Stomach Cancer
Avatar

1L Chemo for Stage 4 Gastroesophageal Cancers: Doublet vs. Triplet

By Hope for Stomach Cancer FEATURING Daniel Catenacci
By Hope for Stomach Cancer FEATURING Daniel Catenacci
0 views
December 19, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Featured Video

15:07
Exelixis

Safety and Efficacy Data of a TKI Monotherapy in HCC

Feat. J. Mizrahi

Recommended

AUTOPLAY
27:37
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Expert Panel Discussion: Practice-Changing Updates

Feat. N. Uboha, A. Turk, K. Spencer, M. Cecchini
09:05
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Expert Panel Discussion on Upper-GI Cancer…

Feat. N. Uboha, A. Turk, K. Spencer, M. Cecchini
23:58
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Key Studies

Feat. R. Kim, R. Mehta
27:12
Moffitt Cancer Center

Year in Review: Upper GI Cancers

Feat. R. Kim, R. Mehta
13:47
Aditya Shreenivas

Neoadjuvant IO in MSI-High GI Cancers: Special Focus on the DREAM GI…

Feat. S. Chakrabarti
07:35
Insights from 2024 ASCO® GI Annual Meeting

ASCO® GI 2024 Summary: "Gastro-Esophageal Key Studies Including…

Feat. R. Kim, R. Mehta
09:42
Insights from 2024 ASCO® GI Annual Meeting

ASCO® GI 2024 Panel Discussion: "MATTERHORN & KEYNOTE-585 C…

Feat. Y. Janjigian, S. Cytryn, S. Klempner
23:27
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "GI Key Studies Including MATTERHORN & K…

Feat. R. Kim, R. Mehta
17:23
Insights from 2024 ASCO® GI Annual Meeting

ASCO® GI 2024 Summary: "Esophageal Squamous Cell Carcinoma Key …

Feat. R. Kim, R. Mehta
09:58
Elizabeth Smyth

Controversies in the Predictive Value of PD-L1 for Anti-PD-1 Benefit…

Feat. R. Sundar
18:51
Hope for Stomach Cancer

1L Therapy for Stage 4 Gastroesophageal Cancers: The Role of Biomark…

Feat. D. Catenacci
10:23
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "Randomized Phase 3 GASTFOX Study - 5-fluor…

Feat. A. Zaanan
06:53
Insights from 2024 ASCO® GI Annual Meeting

ASCO® GI 2024 Panel Discussion: "SKYSCRAPER-08 Clinical Implica…

Feat. Y. Janjigian, S. Cytryn, S. Klempner
04:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Biomarker Analysis of 2 Zolbetuximab Phas…

Feat. K. Shitara
03:31
ecancer

ESMO 2023 Summary: "Highlights From Recent GI Cancer Trials&quo…

Feat. B. Gyawali
08:35
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Phase 3 ATTRACTION-5 Study - Nivo + Chemo…

Feat. M. Terashima
04:01
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "3Yr Follow-Up of RATIONALE-306 - Tisleliz…

Feat. H. Yoon
15:47
Integrity CE

Resectable GEJ Adenocarcinoma: Case Presentation and Expert Panel Di…

Feat. K. Bever, R. Voong, J. Hernandez, S. Klempner
27:39
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Upper-GI Key Studies Including ESOPEC and …

Feat. R. Kim, R. Mehta
11:02
ASCO GI 2023 Conference Coverage

ASCO GI 2023 3-Year Follow-Up From CheckMate 649: Nivo + Chemo vs. C…

Feat. Y. Y. Janjigian